Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Citigroup Downgrades Warby Parker to Neutral, Lowers Price Target to $13

Citigroup Downgrades Warby Parker to Neutral, Lowers Price Target to $13

Citigroup analyst Paul Lejuez downgrades Warby Parker (NYSE:WRBY) from Buy to Neutral and lowers the price target from $26 to $13.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Citigroup analyst Paul Lejuez downgrades Warby Parker (NYSE:WRBY) from Buy to Neutral and lowers the price target from $26 to $13.

Bitcoin Breaks $50,000 Mark, Fueled By ETF Inflows

By Murtuza Merchant

February 12, 2:02 PM

Bitcoin (CRYPTO: BTC) experienced a notable surge on Monday, briefly touching the $50,300 mark, buoyed by a week of strong exchange-traded fund (ETF) inflows and signs of

BTC

Analyst Ratings

The Latest Analyst Ratings for Corvus Pharma

By Benzinga Insights

June 16, 3:00 PM

Over the past 3 months, 4 analysts have published their opinion on Corvus Pharma (NASDAQ:CRVS) stock. These analysts…

CRVS

Analyst Ratings

Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here’s What You Need To Know

By Benzinga Insights

April 17, 1:00 PM

Wedbush has decided to maintain its Neutral rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from…

APLS

Analyst Ratings

The Latest Analyst Ratings for IDEAYA Biosciences

By Benzinga Insights

August 11, 2:00 PM

IDEAYA Biosciences (NASDAQ:IDYA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

IDYA

Citigroup Downgrades Warby Parker to Neutral, Lowers Price Target to $13

Related Posts

Bitcoin Breaks $50,000 Mark, Fueled By ETF Inflows

The Latest Analyst Ratings for Corvus Pharma

Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here’s What You Need To Know

The Latest Analyst Ratings for IDEAYA Biosciences